Altman Peter

Reported to SECin USFilings at 1 company

No score on this page, by design. These filings come from the American register (SEC). We show them as facts, with what the share price did since each filing and since each trade; our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent filings by this filer, out of 16. Reading the whole list, and the full version of the page each row opens (that page itself opens free, with its first rows), is part of the subscription. So are this filer’s key figures and the price change beside each line, since the filing and since the trade. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first. Reported is the day the filing reached the regulator, usually a few days after the trade itself.

5 of 16
Reported insider transactions
CompanyTypeValueReportedCompanyValueTypeSharesReported
BioCardia, Inc.President and CEOOpen-market buy$1,0301,000 sharesSep 30, 2026BioCardia, Inc.President and CEO$1,030Buy · Sep 30Open-market buy1,000Sep 30, 2026
BioCardia, Inc.President and CEOOpen-market buy$1,9951,900 sharesSep 23, 2026BioCardia, Inc.President and CEO$1,995Buy · Sep 23Open-market buy1,900Sep 23, 2026
BioCardia, Inc.President and CEOOpen-market buy$872800 sharesSep 4, 2026BioCardia, Inc.President and CEO$872Buy · Sep 4Open-market buy800Sep 4, 2026
BioCardia, Inc.President and CEOOpen-market buy$5,0225,400 sharesAug 18, 2026BioCardia, Inc.President and CEO$5,022Buy · Aug 18Open-market buy5,400Aug 18, 2026
BioCardia, Inc.President and CEOOpen-market buy$1,7481,900 sharesAug 13, 2026BioCardia, Inc.President and CEO$1,748Buy · Aug 13Open-market buy1,900Aug 13, 2026